Sumitomo Chemical to Construct a New Manufacturing Plant カジノ シークレット 入金 不要ctive Pharmaceutical Ingredients and Intermediates for Small Molecule Drugs at Oita Works in Japan
Supplying a variety of high-quality products as a leading CDMO in Japan

Mar. 30, 2022

Sumitomo Chemical Co., Ltd. will construct a new manufacturing plant カジノ シークレット 入金 不要ctive pharmaceutical ingredients (APIs) and intermediates for small molecule drugs at its Oita Works (Oita City, Oita Prefecture, Japan). This project is to enhance the Company’s capacity to supply a variety of high-quality APIs and intermediates in response to the increasing demand for small molecule drugs. The new plant is scheduled to come on stream in September 2024.

Pharmaceuticals with low molecular weight, called small molecule drugs^*1, are produced by chemical synthesis. Leveraging the strengths in advanced organic synthesis technology and process engineering it has refined as a diversified chemical company, カジノ シークレット 入金 不要 engages in the contract manufacturing of small molecule drug APIs and intermediates for pharmaceutical companies in its Contract Development and Manufacturing Organization (“CDMO”) business and also produces and supplies APIs by using its proprietary manufacturing processes. The global CDMO market, which is currently valued at approximately 10 trillion yen^*2, is expected to continue growing steadily driven by robust demand due to an increase in new drug development programs. Over the years, カジノ シークレット 入金 不要mpany has been strengthening its CDMO business, and has established a leading position in Japan, building on its outstanding quality assurance system and global supply chain management.

The new plant at Oita Works can manufacture a wide variety of APIs and intermediates that require complex chemical reactions and also flexibly scale from development to commercialization, meeting the extensive needs of pharmaceutical companies. In addition, the plant is compliant with the US, EU and Japanese GMP^*3, regulatory standards for pharmaceutical manufacturing and quality management, enabling the supply of high-quality products globally. カジノ シークレット 入金 不要mpany currently produces small molecule drug APIs and intermediates mainly at its Gifu Plant (Anpachi-Cho, Gifu Prefecture, Japan) and Okayama Plant (Kurashiki City, Okayama Prefecture, Japan). By adding the new plant at Oita Works as its third production site, カジノ シークレット 入金 不要mpany aims to enhance its supply capacity as well as reinforce its business continuity plan (BCP). At Oita Works, meanwhile, カジノ シークレット 入金 不要nstruction of a manufacturing plant for drug substances for nucleic acid drugs, which are classified as middle molecule drugs, was started in October 2021. Furthermore, the manufacturing facilities of Sumitomo Dainippon Pharma Co., Ltd.^*4,a subsidiary of カジノ シークレット 入金 不要, are also located in Oita Works. The Company will continue to enhance Oita Works as the core manufacturing site for the カジノ シークレット 入金 不要 Group’s life science operations.

In the new Corporate Business Plan for FY2022 to FY2024, カジノ シークレット 入金 不要 is committed to advancing a broadly-defined green transformation (GX) and helping resolve major social issues, such as carbon neutrality and the promotion of healthy lives, by devoting its capabilities as a diversified chemical company. The Company will steadily supply high-quality small molecule drug APIs and intermediates on a larger scale by leveraging the new plant it has decided to construct, and continue contributing to the healthy lives of the people around the world.

*1 Small molecule drugs are pharmaceuticals with a molecular weight of less than about 500, many of which are administered orally.
*2 Source: Result and Healthcare (2019)
*3 The abbreviation of “Good Manufacturing Practices.”
*4 Sumitomo Dainippon Pharma Co., Ltd. will change its trade name to “Sumitomo Pharma Co., Ltd.” as of April 1, 2022.

カジノ シークレット 入金 不要’s Manufacturing Sites for Small Molecule Drug APIs and Intermediates

Reference:

News Release dated March 3, 2022, “カジノ シークレット 入金 不要 Launches New Corporate Business Plan for FY2022 to FY2024: Achieving Growth Driven by Green Transformation, Investing 1.3 Trillion Yen over Three Years”

News Release dated October 4, 2021, “カジノ シークレット 入金 不要 to Construct a New Manufacturing Plant for Nucleic Acid Drug Substances at Oita Works in Japan: Established the world's first large-scale production technology for high-purity gRNA for genome editing therapy”

Contact

カジノ シークレット 入金 不要 Co., Ltd.
Corporate Communications Dept.
カジノ シークレット 無料 ボーナス Address